Visudyne

The following is a description of the procedure that Dr. Rosen and I discussed on my last visit. The decision was that we would wait for about a month, December 1st is the schedule, to recheck the diseases progress.

FDA Approves Treatment for Wet Macular Degeneration (April 14)
FDA approved the first therapy to slow vision loss from the classic type of Wet Age-Related Macular Degeneration (AMD). FDA approved verteporfin for injection (Visudyne). The European Medicines Evaluation Agency’s Committee for Proprietary Medicinal Product also recommended granting marketing authorization for Visudyne //www.qlt-pdt.com/corporate/html/news8.html). Visudyne therapy is a two-step combination drug and device treatment, which takes about 20 minutes and can be performed in a doctor's office. First, Visudyne is injected intravenously into the patient's arm. The drug is activated in the abnormal vessels in the eye by a laser light. Visudyne is co-developed by QLT PhotoTherapeutics Inc. and CIBA Vision Corp.